Nicolas A. Menzies
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nicolas A. Menzies.
PLOS Medicine | 2012
Nicolas A. Menzies; Ted Cohen; Hsien-Ho Lin; Megan Murray; Joshua A. Salomon
Nicolas Menzies and colleagues investigate the potential impact and cost-effectiveness of implementing Xpert MTB/RIF for diagnosing tuberculosis in five southern African countries.
The Lancet Global Health | 2014
Jeffrey W. Eaton; Nicolas A. Menzies; John Stover; Valentina Cambiano; Leonid Chindelevitch; Anne Cori; Jan A.C. Hontelez; Salal Humair; Cliff C. Kerr; Daniel J. Klein; Sharmistha Mishra; Kate M. Mitchell; Brooke E. Nichols; Peter Vickerman; Roel Bakker; Till Bärnighausen; Anna Bershteyn; David E. Bloom; Marie-Claude Boily; Stewart T. Chang; Ted Cohen; Peter J. Dodd; Christophe Fraser; Chaitra Gopalappa; Jens D. Lundgren; Natasha K. Martin; Evelinn Mikkelsen; Elisa Mountain; Quang D. Pham; Michael Pickles
BACKGROUND New WHO guidelines recommend initiation of antiretroviral therapy for HIV-positive adults with CD4 counts of 500 cells per μL or less, a higher threshold than was previously recommended. Country decision makers have to decide whether to further expand eligibility for antiretroviral therapy accordingly. We aimed to assess the potential health benefits, costs, and cost-effectiveness of various eligibility criteria for adult antiretroviral therapy and expanded treatment coverage. METHODS We used several independent mathematical models in four settings-South Africa (generalised epidemic, moderate antiretroviral therapy coverage), Zambia (generalised epidemic, high antiretroviral therapy coverage), India (concentrated epidemic, moderate antiretroviral therapy coverage), and Vietnam (concentrated epidemic, low antiretroviral therapy coverage)-to assess the potential health benefits, costs, and cost-effectiveness of various eligibility criteria for adult antiretroviral therapy under scenarios of existing and expanded treatment coverage, with results projected over 20 years. Analyses assessed the extension of eligibility to include individuals with CD4 counts of 500 cells per μL or less, or all HIV-positive adults, compared with the previous (2010) recommendation of initiation with CD4 counts of 350 cells per μL or less. We assessed costs from a health-system perspective, and calculated the incremental cost (in US
AIDS | 2011
Nicolas A. Menzies; Andres A. Berruti; Richard Berzon; Scott Filler; Robert Ferris; Tedd V. Ellerbrock; John M. Blandford
) per disability-adjusted life-year (DALY) averted to compare competing strategies. Strategies were regarded very cost effective if the cost per DALY averted was less than the countrys 2012 per-head gross domestic product (GDP; South Africa:
PLOS ONE | 2012
Nicolas A. Menzies; Andres A. Berruti; John M. Blandford
8040; Zambia:
The Lancet Global Health | 2014
Daniel Keebler; Paul Revill; Scott Braithwaite; Andrew N. Phillips; Nello Blaser; Annick Borquez; Valentina Cambiano; Andrea Ciaranello; Janne Estill; Richard Gray; Andrew Hill; Olivia Keiser; Jason Kessler; Nicolas A. Menzies; Kimberly Nucifora; Luisa Salazar Vizcaya; Simon Walker; Alex Welte; Philippa Easterbrook; Meg Doherty; Gottfried Hirnschall; Timothy B. Hallett
1425; India:
Pediatric Infectious Disease Journal | 2009
Nicolas A. Menzies; Jaco Homsy; Jeannie Y. Chang Pitter; Christian Pitter; Jonathan Mermin; Robert Downing; Thomas Finkbeiner; John Obonyo; Adeodata Kekitiinwa; Jordan W. Tappero; John M. Blandford
1489; Vietnam:
AIDS | 2014
Carel Pretorius; Nicolas A. Menzies; Leonid Chindelevitch; Ted Cohen; Anne Cori; Jeffrey W. Eaton; Christophe Fraser; Chaitra Gopalappa; Timothy B. Hallett; Joshua A. Salomon; John Stover; Richard G. White; Peter J. Dodd
1407) and cost effective if the cost per DALY averted was less than three times the per-head GDP. FINDINGS In South Africa, the cost per DALY averted of extending eligibility for antiretroviral therapy to adult patients with CD4 counts of 500 cells per μL or less ranged from
The Lancet Global Health | 2016
Rein M. G. J. Houben; Nicolas A. Menzies; Tom Sumner; Grace H. Huynh; Nimalan Arinaminpathy; Jeremy D. Goldhaber-Fiebert; Hsien-Ho Lin; Chieh Yin Wu; Sandip Mandal; Surabhi Pandey; Sze chuan Suen; Eran Bendavid; Andrew S. Azman; David W. Dowdy; Nicolas Bacaër; Allison S. Rhines; Marcus W. Feldman; Andreas Handel; Christopher C. Whalen; Stewart T. Chang; Bradley G. Wagner; Philip A. Eckhoff; James M. Trauer; Justin T. Denholm; Emma S. McBryde; Ted Cohen; Joshua A. Salomon; Carel Pretorius; Marek Lalli; Jeffrey W. Eaton
237 to
The Lancet Global Health | 2016
Nicolas A. Menzies; Gabriela B. Gomez; Fiammetta Bozzani; Susmita Chatterjee; Nicola Foster; Inés Garcia Baena; Yoko V. Laurence; Sun Qiang; Andrew Siroka; Sedona Sweeney; Stéphane Verguet; Nimalan Arinaminpathy; Andrew S. Azman; Eran Bendavid; Stewart T. Chang; Ted Cohen; Justin T. Denholm; David W. Dowdy; Philip A. Eckhoff; Jeremy D. Goldhaber-Fiebert; Andreas Handel; Grace H. Huynh; Marek Lalli; Hsien-Ho Lin; Sandip Mandal; Emma S. McBryde; Surabhi Pandey; Joshua A. Salomon; Sze chuan Suen; Tom Sumner
1691 per DALY averted compared with 2010 guidelines. In Zambia, expansion of eligibility to adults with a CD4 count threshold of 500 cells per μL ranged from improving health outcomes while reducing costs (ie, dominating the previous guidelines) to
International Journal of Tuberculosis and Lung Disease | 2014
David W. Dowdy; Rein M. G. J. Houben; Ted Cohen; Madhukar Pai; Frank Cobelens; Anna Vassall; Nicolas A. Menzies; Gabriela B. Gomez; Ivor Langley; S. B. Squire; Richard G. White
749 per DALY averted. In both countries results were similar for expansion of eligibility to all HIV-positive adults, and when substantially expanded treatment coverage was assumed. Expansion of treatment coverage in the general population was also cost effective. In India, the cost for extending eligibility to all HIV-positive adults ranged from
Collaboration
Dive into the Nicolas A. Menzies's collaboration.
